Global Ketolides Market Size, Trends, and Growth Opportunity, By Indication (Sinusitis, Tonsillitis/Pharyngitis, Bronchitis, Pneumonia), Drug Type (Cethromycin, Telithromycin, Solithromycin), Microorganism (Haemophilus influenza, Moraxella catarrhalis, Streptococcus pneumoniae, Chlamydophila pneumonia, and Mycoplasma pneumoniae), Population Type (Children and Adults), Disease Type (Mild and Severe), Dosage Type (Oral and Parenteral), Mode of Purchase (Over the Counter and Prescription), End User (Specialty Clinics, Hospitals, and Others), Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies, and Others) By Region and forecast till 2030.
Global Ketolides Market
Global Ketolides Market was valued at USD 3.02 Billion in 2022 and is slated to reach USD 4.11 Billion by 2030 at a CAGR of 4.24 % from 2023-2030.
To combat S. pneumoniae macrolide resistance, a new class of semi-synthetic drugs called ketolides, derived from erythromycin A, has been developed. Gram-positive bacteria and intracellular infections including mycoplasma, chlamydia, and legionella are both successfully combatted by these drugs. Treatment of upper and lower respiratory tract infections that are mild to moderate in severity and acquired in the community is the primary clinical indication for the use of ketolides.
Market Drivers
The prevalence of infectious diseases is rising, which is driving market expansion. Between 2009 and 2017, there were 71.8 infectious illness syndromes per 10,000 people nationwide. Every year, there were around 14,519 infectious disorders (with a range of 5229 to 55,132). The market is growing as a result of the higher acceptance of ketolides due to the rising occurrence of infectious disorders. The market is expanding as a result of the rising demand for telithromycin. A wide variety of respiratory infections, such as intracellular bacteria, penicillin- and erythromycin-resistant pneumococci, and unusual microorganisms are all responsive to telithromycin. In both young and old people, it has a kind of oral availability of 57%, and food has no impact on the rate or amount of absorption. As a result, this component spurs market expansion.
Market Restraints
Ketolides have several adverse effects that limit commercial expansion. Ketolides frequently cause nausea, diarrhea, and vomiting as adverse effects. In patients with hepatic impairment, telithromycin should be avoided because it has been linked to possibly deadly hepatotoxicity. In a black box warning, the U.S. Food and Drug Administration (FDA) stated that people with myasthenia gravis should not take telithromycin. This consequently hinders the market.
Impact of COVID-19
Due to the high prevalence of secondary bacterial infections in COVID-19 patients, the pandemic has resulted in a rise in the demand for antibiotics, notably ketolides. A shortage of antibiotics, especially ketolides, has emerged in some areas due to the interruption of the supply chain and the redirection of resources to combat the COVID-19 epidemic. Furthermore, the COVID-19 pandemic has hampered clinical trials for novel ketolides, delaying their approval and commercialization. The expansion of the market for ketolides worldwide has also been impacted by this.
Market Segmentation
Global Ketolides Market is segmented By Indication, Microorganism, Population Type, Drug Type, Disease Type, Mode of Purchase, End User, Dosage Type, and Distribution Channel. By Indications such as Sinusitis, Tonsillitis/Pharyngitis, Bronchitis, and Pneumonia. By Drug Type such as Cethromycin, Telithromycin, and Solithromycin. By Microorganisms such as Haemophilus influenza, Moraxella catarrhalis, Streptococcus pneumoniae, Chlamydophila pneumoniae, and Mycoplasma pneumonia. By Population Types such as Children and Adults. By Disease Type such as Mild and Severe. By Dosage Types such as Oral and Parenteral. By Mode of Purchase such as Over Counter and Prescription. By End Users such as Specialty Clinics, Hospitals, and Others. By Distribution channels such as Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Others.
Regional Analysis
Global Ketolides Market is segmented into five regions Americas, Europe, Asia-Pacific, and the Middle East & Africa. Because of the rise in infectious disorders and greater prescription rates in Asia-Pacific, the market for ketolides is predicted to expand throughout this period. Due to the rise in bacterial skin infections in the region, North America will continue to lead the market throughout the projection period. Because of its developed healthcare infrastructure, growing public awareness, and expanded research and development, the United States controls a significant percentage of the market in North America compared to other nations in the region.
Key Players
This report includes a list of numerous Key Players, namely F. Hoffmann-La Roche Ltd (Switzerland), and WOCKHARDT. (India), Novartis AG (Switzerland), Abbott (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (U.S.), Eli Lilly and Company (U.S.), Alembic Pharmaceuticals Limited (India), Pfizer Inc. (U.S.), Bristol-Myers Squibb Company (U.S.).
Market Taxonomy
By Indication
• Bronchitis
• Pneumonia
• Sinusitis
• Tonsillitis/Pharyngitis
By Drug Type
• Telithromycin
• Cethromycin,
• Solithromycin
By Microorganism
• Streptococcus Pneumoniae
• Haemophilus Influenzae
• Moraxella Catarrhalis
• Chlamydophila Pneumoniae
• Mycoplasma Pneumoniae
By Population Type
• Children
• Adults
By Disease Type
• Mild
• Severe
By Dosage Type
• Oral
• Parenteral
By Mode of Purchase
• Over the Counter
• Prescription
By End User
• Hospitals
• Specialty Clinics
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others
By Region
• North America Latin America
• Europe
• Asia Pacific
• Middle East & Africa.
Global Ketolides Market
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Ketolides Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact due to recent Energy Crisis
4.2.5 Cumulative Impact due to nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Ketolides Market, By Indication
5.1 Y-o-Y Growth Comparison, By Indication
5.2 Global Ketolides Market Share Analysis, By Indication
5.3 Global Ketolides Market Size and Forecast, By Indication
5.3.1 Bronchitis
5.3.2 Pneumonia
5.3.3 Sinusitis
5.3.3 Tonsillitis/Pharyngitis
6 Global Ketolides Market, By Drug Type
6.1 Y-o-Y Growth Comparison, By Drug Type
6.2 Global Ketolides Market Share Analysis, By Drug Type
6.3 Global Ketolides Market Size and Forecast, By Drug Type
6.3.1 Telithromycin
6.3.2 Cethromycin,
6.3.3 Solithromycin
7 Global Ketolides Market, By Microorganism
7.1 Y-o-Y Growth Comparison, By Microorganism
7.2 Global Ketolides Market Share Analysis, By Microorganism
7.3 Global Ketolides Market Size and Forecast, By Microorganism
7.3.1 Streptococcus Pneumoniae
7.3.2 Haemophilus Influenzae
7.3.3 Moraxella Catarrhalis
7.3.4 Chlamydophila Pneumoniae
7.3.5 Mycoplasma Pneumoniae
8 Global Ketolides Market, By Population Type
8.1 Y-o-Y Growth Comparison, By Population Type
8.2 Global Ketolides Market Share Analysis, By Population Type
8.3 Global Ketolides Market Size and Forecast, By Population Type
8.3.1 Children
8.3.2 Adults
9 Global Ketolides Market, By Disease Type
9.1 Y-o-Y Growth Comparison, By Disease Type
9.2 Global Ketolides Market Share Analysis, By Disease Type
9.3 Global Ketolides Market Size and Forecast, By Disease Type
9.3.1 Mild
9.3.2 Severe
10 Global Ketolides Market, By Dosage Type
10.1 Y-o-Y Growth Comparison, By Dosage Type
10.2 Global Ketolides Market Share Analysis, By Dosage Type
10.3 Global Ketolides Market Size and Forecast, By Dosage Type
10.3.1 Oral
10.3.2 Parenteral
11 Global Ketolides Market, By Mode of Purchase
11.1 Y-o-Y Growth Comparison, By Mode of Purchase
11.2 Global Ketolides Market Share Analysis, By Mode of Purchase
11.3 Global Ketolides Market Size and Forecast, By Mode of Purchase
11.3.1 Over the Counter
11.3.2 Prescription
12 Global Ketolides Market, By Distribution Channel
12.1 Y-o-Y Growth Comparison, By Distribution Channel
12.2 Global Ketolides Market Share Analysis, By Distribution Channel
12.3 Global Ketolides Market Size and Forecast, By Distribution Channel
12.3.1 Hospital Pharmacies
12.3.2 Retail Pharmacies
12.3.3 Online Pharmacies
12.3.4 Others
13 Global Ketolides Market, By End User
13.1 Y-o-Y Growth Comparison, By End User
13.2 Global Ketolides Market Share Analysis, By End User
13.3 Global Ketolides Market Size and Forecast, By End User
13.3.1 Hospitals
13.3.2 Specialty Clinics
13.3.3 Others
14 Global Ketolides Market, By Region
14.1 Global Ketolides Market Share Analysis, By Region
14.2 Global Ketolides Market Share Analysis, By Region
14.3 Global Ketolides Market Size and Forecast, By Region
15 North America Ketolides Market Analysis and Forecast (2023-2030)
15.1 Introduction
15.2 North America Ketolides Market Share Analysis, By Indication
15.3 North America Ketolides Market Share Analysis, By Drug Type
15.4 North America Ketolides Market Share Analysis, By Microorganism
15.5 North America Ketolides Market Share Analysis, By Population Type
15.6 North America Ketolides Market Share Analysis, By Disease Type
15.7 North America Ketolides Market Share Analysis, By Dosage Type
15.8 North America Ketolides Market Share Analysis, By Mode of Purchase
15.9 North America Ketolides Market Share Analysis, By Distribution Channel
15.10 North America Ketolides Market Share Analysis, By End User
15.11 North America Ketolides Market Size and Forecast, By Country
15.11.1 U.S.
15.11.2 Canada
15.11.3 Mexico
16 Europe Ketolides Market Analysis and Forecast (2023-2030)
16.1 Introduction
16.2 Europe Ketolides Market Share Analysis, By Indication
16.3 Europe Ketolides Market Size and Forecast, By Drug Type
16.4 Europe Ketolides Market Size and Forecast, By Microorganism
16.5 Europe Ketolides Market Size and Forecast, By Population Type
16.6 Europe Ketolides Market Size and Forecast, By Control Type
16.7 Europe Ketolides Market Size and Forecast, By Dosage Type
16.8 Europe Ketolides Market Size and Forecast, By Mode of Purchase
16.9 Europe Ketolides Market Size and Forecast, By Distribution Channel
16.10 Europe Ketolides Market Share Analysis, By End User
16.11 Europe Ketolides Market Size and Forecast, By Country
16.11.1 Germany
16.11.2 France
16.11.3 UK
16.11.4. Rest of Europe
17 Asia Pacific Ketolides Market Analysis and Forecast (2023-2030)
17.1 Introduction
17.2 Asia Pacific Ketolides Market Share Analysis, By Indication
17.3 Asia Pacific Ketolides Market Size and Forecast, By Drug Type
17.4 Asia Pacific Ketolides Market Size and Forecast, By Microorganism
17.5 Asia Pacific Ketolides Market Size and Forecast, By Population Type
17.6 Asia Pacific Ketolides Market Size and Forecast, By Control Type
17.7 Asia Pacific Ketolides Market Size and Forecast, By Dosage Type
17.8 Asia Pacific Ketolides Market Size and Forecast, By Mode of Purchase
17.9 Asia Pacific Ketolides Market Size and Forecast, By Distribution Channel
17.10 Asia Pacific Ketolides Market Share Analysis, By End User
17.11 Asia Pacific Ketolides Market Size and Forecast, By Country
17.11.1 China
17.11.2 Japan
17.11.3 India
17.11.4. Rest of Asia Pacific
18 Latin America Ketolides Market Analysis and Forecast (2023-2030)
18.1 Introduction
18.2 Latin America Ketolides Market Share Analysis, By Indication
18.3 Latin America Ketolides Market Share Analysis, By Drug Type
18.4 Latin America Ketolides Market Share Analysis, By Microorganism
18.5 Latin America Ketolides Market Share Analysis, By Population Type
18.6 Latin America Ketolides Market Share Analysis, By Disease Type
18.7 Latin America Ketolides Market Share Analysis, By Dosage Type
18.8 Latin America Ketolides Market Share Analysis, By Mode of Purchase
18.9 Latin America Ketolides Market Share Analysis, By Distribution Channel
18.10 Latin America Ketolides Market Share Analysis, By End User
18.11 Latin America Ketolides Market Size and Forecast, Country
18.11.1. Brazil
18.11.2.Rest of Latin America
19 Middle East Ketolides Market Analysis and Forecast (2023-2030)
19.1 Introduction
19.2 Middle East Ketolides Market Share Analysis, By Indication
19.3 Middle East Ketolides Market Size and Forecast, By Drug Type
19.4 Middle East Ketolides Market Size and Forecast, By Microorganism
19.5 Middle East Ketolides Market Size and Forecast, By Population Type
19.6 Middle East Ketolides Market Size and Forecast, By Control Type
19.7 Middle East Ketolides Market Size and Forecast, By Dosage Type
19.8 Middle East Ketolides Market Size and Forecast, By Mode of Purchase
19.9 Middle East Ketolides Market Size and Forecast, By Distribution Channel
19.10 Middle East Ketolides Market Share Analysis, By End User
19.11 Middle East Ketolides Market Size and Forecast, By Country
19.11.1. Saudi Arabia
19.11.2. UAE
19.11.3. Egypt
19.11.4. Kuwait
19.11.5. South Africa
20 Competitive Analysis
20.1 Competition Dashboard
20.2 Market share Analysis of Top Vendors
20.3 Key Development Strategies
21 Company Profiles
21.1 F. Hoffmann-La Roche Ltd (Switzerland)
21.1.1 Overview
21.1.2 Offerings
21.1.3 Key Financials
21.1.4 Business Segment & Geographic Overview
21.1.5 Key Market Developments
21.1.6 Key Strategies
21.2. WOCKHARDT. (India)
21.2.1 Overview
21.2.2 Offerings
21.2.3 Key Financials
21.2.4 Business Segment & Geographic Overview
21.2.5 Key Market Developments
21.2.6 Key Strategies
21.3. Novartis AG (Switzerland)
21.3.1 Overview
21.3.2 Offerings
21.3.3 Key Financials
21.3.4 Business Segment & Geographic Overview
21.3.5 Key Market Developments
21.3.6 Key Strategies
21.4 Abbott (U.S.)
21.4.1 Overview
21.4.2 Offerings
21.4.3 Key Financials
21.4.4 Business Segment & Geographic Overview
21.4.5 Key Market Developments
21.4.6 Key Strategies
21.5 Teva Pharmaceutical Industries Ltd. (Israel)
21.5.1 Overview
21.5.2 Offerings
21.5.3 Key Financials
21.5.4 Business Segment & Geographic Overview
21.5.5 Key Market Developments
21.5.6 Key Strategies
21.6 Merck & Co., Inc. (U.S.)
21.6.1 Overview
21.6.2 Offerings
21.6.3 Key Financials
21.6.4 Business Segment & Geographic Overview
21.6.5 Key Market Developments
21.6.6 Key Strategies
21.7 Eli Lilly and Company (U.S.)
21.7.1 Overview
21.7.2 Offerings
21.7.3 Key Financials
21.7.4 Business Segment & Geographic Overview
21.7.5 Key Market Developments
21.7.6 Key Strategies
21.8 Alembic Pharmaceuticals Limited (India)
21.8.1 Overview
21.8.2 Offerings
21.8.3 Key Financials
21.8.4 Business Segment & Geographic Overview
21.8.5 Key Market Developments
21.8.6 Key Strategies
21.9 Pfizer Inc. (U.S.)
21.9.1 Overview
21.9.2 Offerings
21.9.3 Key Financials
21.9.4 Business Segment & Geographic Overview
21.9.5 Key Market Developments
21.9.6 Key Strategies
21.10 Bristol-Myers Squibb Company (U.S.)
21.10.1 Overview
21.10.2 Offerings
21.10.3 Key Financials
21.10.4 Business Segment & Geographic Overview
21.10.5 Key Market Developments
21.10.6 Key Strategies
